Abstract
Clofarabine, an approved anticancer drug, was evaluated in combination with radiation in six subcutaneously implanted human tumor xenograft models. Clofarabine had no effect on the growth of SF-295 glioblastoma, which was not enhanced by radiation. There was no difference between clofarabine with and without radiation in the DU-145 prostate model. The combined effect on NCI-H460 lung tumors appeared to be additive. SR475 head and neck, PANC-1 pancreatic, and HCT-116 colon tumors were radiomodified by clofarabine. The radiomodifying capacity of clofarabine was superior to that for gemcitabine in two models (PANC-1 and HCT-116) and was comparable in the other four models.
MeSH terms
-
Adenine Nucleotides / administration & dosage
-
Adenine Nucleotides / therapeutic use*
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Arabinonucleosides / administration & dosage
-
Arabinonucleosides / therapeutic use*
-
Cell Line, Tumor
-
Clofarabine
-
Combined Modality Therapy
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Drug Evaluation, Preclinical
-
Gemcitabine
-
Humans
-
Mice
-
Mice, Nude
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / radiotherapy
-
Neoplasms, Experimental / therapy*
-
Tumor Burden / drug effects
-
Xenograft Model Antitumor Assays
Substances
-
Adenine Nucleotides
-
Antineoplastic Agents
-
Arabinonucleosides
-
Deoxycytidine
-
Clofarabine
-
Gemcitabine